The “magnificent seven” tech stocks have helped drive the U.S. stock market to record highs. Their soaring valuations imply ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side ...

"Trump might forget about Greenland. But also, he might not. Nobody knows. He operates on whims," @anneapplebaum writes.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

and to work with like-minded suppliers. One way to ensure that Novo Nordisk’s approach to sustainability is carried through all parts of the business has been the way it has approached educating ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Novo Nordisk describes its latest work as "a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration." ...

Novo Nordisk - which manufactures Wegovy ... Image: Pic: Reuters file photo Weight loss jabs, known as GLP-1 receptor agonists, work by reducing food cravings. Hundreds of thousands of patients ...